A structural analog , also known as a chemical analog or simply an analog , is a compound having a structure similar to that of another compound, but differing from it in respect to a certain component.
72-534: Cyclooxygenase-2 inhibitors ( COX-2 inhibitors ), also known as coxibs , are a type of nonsteroidal anti-inflammatory drug (NSAID) that directly target cyclooxygenase-2 ( COX-2 ), an enzyme responsible for inflammation and pain . Targeting selectivity for COX-2 reduces the risk of peptic ulceration and is the main feature of celecoxib , rofecoxib , and other members of this drug class. After several COX-2–inhibiting drugs were approved for marketing, data from clinical trials revealed that COX-2 inhibitors caused
144-465: A diuretic (which drops plasma volume, and thereby RPF)—the so-called "triple whammy" effect. In rarer instances NSAIDs may also cause more severe kidney conditions: NSAIDs in combination with excessive use of phenacetin or paracetamol (acetaminophen) may lead to analgesic nephropathy . Photosensitivity is a commonly overlooked adverse effect of many of the NSAIDs. The 2-arylpropionic acids are
216-426: A COX-2 inhibitor, the restored p53 function allows DNA damaged neuroblastoma cells to commit suicide through apoptosis reducing the size of growth of the tumor. Nonsteroidal anti-inflammatory drug Non-steroidal anti-inflammatory drugs ( NSAID ) are members of a therapeutic drug class which reduces pain , decreases inflammation , decreases fever , and prevents blood clots . Side effects depend on
288-572: A database is screened for structural analogs of a lead compound . Chemical analogues of illegal drugs are developed and sold in order to circumvent laws. Such substances are often called designer drugs . Because of this, the United States passed the Federal Analogue Act in 1986. This bill banned the production of any chemical analogue of a Schedule I or Schedule II substance that has substantially similar pharmacological effects, with
360-591: A doubled risk of heart failure in people without a history of cardiac disease. In people with such a history, use of NSAIDs (aside from low-dose aspirin) was associated with a more than 10-fold increase in heart failure. If this link is proven causal, researchers estimate that NSAIDs would be responsible for up to 20 percent of hospital admissions for congestive heart failure. In people with heart failure, NSAIDs increase mortality risk ( hazard ratio ) by approximately 1.2–1.3 for naproxen and ibuprofen, 1.7 for rofecoxib and celecoxib, and 2.1 for diclofenac. On 9 July 2015,
432-404: A fairly high incidence of adverse drug reactions ( ADRs ) on the kidney and over time can lead to chronic kidney disease . The mechanism of these kidney ADRs is due to changes in kidney blood flow. Prostaglandins normally dilate the afferent arterioles of the glomeruli . This helps maintain normal glomerular perfusion and glomerular filtration rate (GFR), an indicator of kidney function . This
504-511: A more generalized drug intolerance to NSAIDs, and caution should be exercised in those with asthma or NSAID -precipitated bronchospasm . Owing to its effect on the stomach lining, manufacturers recommend people with peptic ulcers , mild diabetes , or gastritis seek medical advice before using aspirin. Use of aspirin during dengue fever is not recommended owing to increased bleeding tendency. People with kidney disease , hyperuricemia , or gout should not take aspirin because it inhibits
576-440: A reduced risk of GI ulceration. Numerous "gastro-protective" drugs have been developed with the goal of preventing gastrointestinal toxicity in people who need to take NSAIDs on a regular basis. Gastric adverse effects may be reduced by taking medications that suppress acid production such as proton pump inhibitors (e.g.: omeprazole and esomeprazole ), or by treatment with a drug that mimics prostaglandin in order to restore
648-501: A significant increase in heart attacks and strokes, with some drugs in the class having worse risks than others. Rofecoxib (sold under the brand name Vioxx) was taken off the market in 2004 because of these concerns, while celecoxib (sold under the brand name Celebrex) and traditional NSAIDs received boxed warnings on their labels. Many COX-2–specific inhibitors have been removed from the US market. As of December 2011, only Celebrex (celecoxib)
720-500: A single dose to treat pain after surgery. In this role etoricoxib appears as good as, if not better than, other pain medications, and celecoxib appears to be about as useful as ibuprofen . NSAIDs are often used in treatment of acute gout attacks. COX-2 inhibitors appear to work as well as nonselective NSAIDs, such as aspirin. They have not been compared to other treatment options such as colchicine or glucocorticoids . COX-2 appears to be related to cancers and abnormal growths in
792-571: Is evidence of increased risk of kidney complications. Their use following gastrointestinal surgery remains controversial, given mixed evidence of increased risk of leakage from any bowel anastomosis created. An estimated 10–20% of people taking NSAIDs experience indigestion . In the 1990s, high doses of prescription NSAIDs were associated with serious upper gastrointestinal adverse events, including bleeding. NSAIDs, like all medications, may interact with other medications. For example, concurrent use of NSAIDs and quinolone antibiotics may increase
SECTION 10
#1732859131251864-518: Is not effective for the treatment or prevention of Alzheimer's disease . NSAIDs may be used with caution by people with the following conditions: NSAIDs should usually be avoided by people with the following conditions: The widespread use of NSAIDs has meant that the adverse effects of these drugs have become increasingly common. Use of NSAIDs increases risk of a range of gastrointestinal (GI) problems, kidney disease and adverse cardiovascular events. As commonly used for post-operative pain, there
936-506: Is particularly important in kidney failure where the kidney is trying to maintain renal perfusion pressure by elevated angiotensin II levels. At these elevated levels, angiotensin II also constricts the afferent arteriole into the glomerulus in addition to the efferent arteriole it normally constricts. Since NSAIDs block this prostaglandin-mediated effect of afferent arteriole dilation, particularly in kidney failure, NSAIDs cause unopposed constriction of
1008-416: Is prudent to use the lowest effective dose for the shortest period of time—a practice that studies show is often not followed. Over 50% of patients who take NSAIDs have sustained some mucosal damage to their small intestine. The risk and rate of gastric adverse effects is different depending on the type of NSAID medication a person is taking. Indomethacin , ketoprofen , and piroxicam use appear to lead to
1080-416: Is regarded as being safe and well tolerated during pregnancy, but Leffers et al. released a study in 2010, indicating that there may be associated male infertility in the unborn. Doses should be taken as prescribed, due to risk of liver toxicity with overdoses. In France, the country's health agency contraindicates the use of NSAIDs, including aspirin, after the sixth month of pregnancy. In October 2020,
1152-435: Is safe, if adequate monitoring is done. NSAIDs, aside from aspirin, increase the risk of myocardial infarction and stroke . This occurs at least within a week of use. They are not recommended in those who have had a previous heart attack as they increase the risk of death or recurrent MI. Evidence indicates that naproxen may be the least harmful out of these. NSAIDs aside from (low-dose) aspirin are associated with
1224-428: Is some low-certainty evidence that starting NSAID painkiller medications in adults early, before surgery, may help reduce post-operative pain, and also reduce the dose or quantity of opioid medications required after surgery. Any increase risk of surgical bleeding, bleeding in the gastrointestinal system, myocardial infarctions, or injury to the kidneys has not been well studied. When used in combination with paracetamol,
1296-561: Is still available for purchase in the United States. In the European Union, celecoxib, parecoxib , and etoricoxib have been approved for use by the European Medicines Agency . Paracetamol (acetaminophen) inhibits COX-2 almost exclusively within the brain and only minimally in the rest of the body, although it is not considered an NSAID, since it has only minor anti-inflammatory activity. Some COX-2 inhibitors are used in
1368-415: Is unknown. Studies have shown that COX-2 inhibitors block the phosphorylation of HDM2 preventing its activation. In vitro, the use of COX-2 inhibitors lowers the level of active HDM2 found in neuroblastoma cells. The exact process of how COX-2 inhibitors block HDM2 phosphorylation is unknown, but this mediated reduction in active HDM2 concentration level restores the cellular p53 levels. After treatment with
1440-456: Is ≈170-fold more potent in inhibiting COX-1 than COX-2. Studies of meloxicam 7.5 mg per day for 23 days find a level of gastric injury similar to that of a placebo , and for meloxicam 15 mg per day a level of injury lower than that of other NSAIDs; however, in clinical practice meloxicam can still cause some ulcer complications. Valdecoxib and rofecoxib were about 300 times more potent at inhibiting COX-2 than COX-1, but too toxic for
1512-519: The Food and Drug Administration (FDA) toughened warnings of increased heart attack and stroke risk associated with nonsteroidal anti-inflammatory drugs (NSAIDs) other than aspirin . A 2005 Finnish survey study found an association between long term (over three months) use of NSAIDs and erectile dysfunction . A 2011 publication in The Journal of Urology received widespread publicity. According to
SECTION 20
#17328591312511584-504: The cytosol . When cellular DNA is damaged beyond repair, p53 is transported to the nucleus where it promotes p53 mediated apoptosis. Two of the metabolites of COX-2, prostaglandin A2 (PGA2) and A1 (PGA1), when present in high quantities, bind to p53 in the cytosol and inhibit its ability to cross into the nucleus. This essentially sequesters p53 in the cytosol and prevents apoptosis. Coxibs such as Celebrex (celecoxib), by selectively inhibiting
1656-461: The gastrointestinal (GI) tract . NSAIDs cause a dual assault on the GI tract: the acidic molecules directly irritate the gastric mucosa , and inhibition of COX-1 and COX-2 reduces the levels of protective prostaglandins . Inhibition of prostaglandin synthesis in the GI tract causes increased gastric acid secretion, diminished bicarbonate secretion, diminished mucus secretion and diminished trophic effects on
1728-615: The Celecoxib Long-term Arthritis Safety Study (CLASS) in JAMA , and the Vioxx Gastrointestinal Outcomes Research (VIGOR). The VIGOR trial was later proven to have been based on faulty data, and Vioxx was eventually withdrawn from the market. The VIGOR (Vioxx Gastrointestinal Outcomes Research) trial, "which was the making of Merck's drug rofecoxib (Vioxx)," was at the center of a dispute about
1800-461: The Reuben studies were removed, the conclusions in the majority of them remained unchanged. The review found that the key Reuben claims that needed to be re-examined were "the absence of detrimental effects of coxibs on bone healing after spine surgery , the beneficial long-term outcome after preemptive administration of coxibs including an allegedly decreased incidence of chronic pain after surgery, and
1872-633: The U.S. Food and Drug Administration (FDA) required the drug label to be updated for all nonsteroidal anti-inflammatory medications, to describe the risk of kidney problems in unborn babies which can then lead to low amniotic fluid levels, as a result of the use of NSAIDs. They are recommending avoiding the use of NSAIDs by pregnant women at 20 weeks or later in pregnancy. Analog (chemistry) It can differ in one or more atoms , functional groups , or substructures, which are replaced with other atoms, groups, or substructures. A structural analog can be imagined to be formed, at least theoretically, from
1944-673: The United States Food and Drug Administration (FDA) sent a warning letter to the CEO of Merck, stating, "Your promotional campaign discounts the fact that in the VIGOR study, patients on Vioxx were observed to have a four to five fold increase in myocardial infarctions (MIs) compared to patients on the comparator nonsteroidal anti-inflammatory drug (NSAID), Naprosyn (naproxen)." This led to the introduction, in April 2002, of warnings on Vioxx labeling concerning
2016-652: The ability of all these compounds to kill tumor cells in cell culture was investigated, it turned out that the antitumor potency did not at all depend on whether or not the respective compound could inhibit COX-2, showing that inhibition of COX-2 was not required for the anticancer effects. One of these compounds, 2,5-dimethyl-celecoxib, which entirely lacks the ability to inhibit COX-2, actually turned out to display stronger anticancer activity than celecoxib itself and this anticancer effect could also be verified in highly drug-resistant tumor cells and in various animal tumor models. Analysis of clinical trial data revealed that there
2088-467: The activity of cyclooxygenase enzymes (the COX-1 and COX-2 isoenzymes ). In cells, these enzymes are involved in the synthesis of key biological mediators, namely prostaglandins , which are involved in inflammation , and thromboxanes , which are involved in blood clotting . There are two general types of NSAIDs available: non-selective and COX-2 selective . Most NSAIDs are non-selective, and inhibit
2160-491: The activity of both COX-1 and COX-2. These NSAIDs, while reducing inflammation, also inhibit platelet aggregation and increase the risk of gastrointestinal ulcers and bleeds. COX-2 selective inhibitors have fewer gastrointestinal side effects, but promote thrombosis , and some of these agents substantially increase the risk of heart attack . As a result, certain COX-2 selective inhibitors—such as rofecoxib —are no longer used due to
2232-422: The afferent arteriole and decreased RPF (renal perfusion flow) and GFR. Common ADRs associated with altered kidney function include: These agents may also cause kidney impairment, especially in combination with other nephrotoxic agents. Kidney failure is especially a risk if the patient is also concomitantly taking an ACE inhibitor (which removes angiotensin II's vasoconstriction of the efferent arteriole) and
Cyclooxygenase-2 inhibitor - Misplaced Pages Continue
2304-452: The analgesic effect on post-operative pain may be improved. Aspirin , the only NSAID able to irreversibly inhibit COX-1 , is also indicated for antithrombosis through inhibition of platelet aggregation . This is useful for the management of arterial thrombosis , and prevention of adverse cardiovascular events like heart attacks. Aspirin inhibits platelet aggregation by inhibiting the action of thromboxane A 2 . NSAIDs are useful in
2376-598: The analgesic efficacy of ketorolac or clonidine when added to local anesthetics for intravenous regional anesthesia ." Celebrex (and other brand names for celecoxib) was introduced in 1999 and rapidly became the most frequently prescribed new drug in the United States. By October 2000, its US sales exceeded 100 million prescriptions per year for $ 3 billion, and was still rising. Sales of Celebrex alone reached $ 3.1 billion in 2001. A Spanish study found that between January 2000 and June 2001, 7% of NSAID prescriptions and 29% of NSAID expenditures were for COX-2 inhibitors. Over
2448-642: The anticancer effects of celecoxib in the absence of COX-2. Moreover, a recent study with various malignant tumor cells showed that celecoxib could inhibit the growth of these cells, even though some of these cancer cells didn't even contain COX-2. Additional support for the idea that other targets besides COX-2 are important for celecoxib's anticancer effects has come from studies with chemically modified versions of celecoxib. Several dozen analogs of celecoxib were generated with small alterations in their chemical structures . Some of these analogs retained COX-2 inhibitory activity, whereas many others didn't. However, when
2520-437: The benefits of pain-relief medications such as NSAIDS and the potential for adverse effects has not been well determined. There is some evidence suggesting that, for some people, use of NSAIDs (or other anti-inflammatories) may contribute to the initiation of chronic pain. Side effects are dose-dependent, and in many cases severe enough to pose the risk of ulcer perforation, upper gastrointestinal bleeding, and death, limiting
2592-547: The brain, and only minimally in the rest of the body. NSAIDs are often suggested for the treatment of acute or chronic conditions where pain and inflammation are present. NSAIDs are generally used for the symptomatic relief of the following conditions: The effectiveness of NSAIDs for treating non-cancer chronic pain and cancer-related pain in children and adolescents is not clear. There have not been sufficient numbers of high-quality randomised controlled trials conducted. Differences in anti-inflammatory activity between
2664-490: The cardiovascular problems became, and remains, a subject of intensive research. As of 2012 results have been converging on the hypothesis that the adverse cardiovascular effects are most likely due to inhibition of COX-2 in blood vessels , which leads to a decrease in the production of prostacyclin in them. Prostacyclin usually prevents platelet aggregation and vasoconstriction , so its inhibition can lead to excess clot formation and higher blood pressure. The COX-2 enzyme
2736-551: The cardiovascular safety of the coxibs (COX-2 inhibitors). A statistically significant increase in the incidence of myocardial infarctions was observed in patients on rofecoxib. Further data, from the APPROVe trial, showed a statistically significant relative risk of cardiovascular events of 1.97 versus placebo —which caused a worldwide withdrawal of rofecoxib in October 2004. Use of methotrexate together with NSAIDs in rheumatoid arthritis
2808-400: The different chromophoric 2-aryl substituents, affects the decarboxylation mechanism. While NSAIDs as a class are not direct teratogens , use of NSAIDs in late pregnancy can cause premature closure of the fetal ductus arteriosus and kidney ADRs in the fetus. Thus, NSAIDs are not recommended during the third trimester of pregnancy because of the increased risk of premature constriction of
2880-400: The ductus arteriosus. Additionally, they are linked with premature birth and miscarriage . Aspirin, however, is used together with heparin in pregnant women with antiphospholipid syndrome . Additionally, indomethacin can be used in pregnancy to treat polyhydramnios by reducing fetal urine production via inhibiting fetal renal blood flow. In contrast, paracetamol (acetaminophen)
2952-478: The epithelial mucosa. Common gastrointestinal side effects include: Clinical NSAID ulcers are related to the systemic effects of NSAID administration. Such damage occurs irrespective of the route of administration of the NSAID (e.g., oral, rectal, or parenteral) and can occur even in people who have achlorhydria . Ulceration risk increases with therapy duration, and with higher doses. To minimize GI side effects, it
Cyclooxygenase-2 inhibitor - Misplaced Pages Continue
3024-505: The ethics of medical journals. In the VIGOR trial, over 8,000 patients were randomized to receive either naproxen or rofecoxib (Vioxx). Both studies concluded that COX-2 specific NSAIDs were associated with significantly fewer adverse gastrointestinal effects. In the CLASS trial which compared Celebrex 800 mg/day to ibuprofen 2400 mg/day and diclofenac 150 mg/day for osteoarthritis or rheumatoid arthritis for six months, Celebrex
3096-440: The gastric ulceration/bleeding associated with taking the NSAIDs alone. Hydrogen sulfide is known to have a protective effect on the cardiovascular and gastrointestinal system. NSAIDs should be used with caution in individuals with inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis ) due to their tendency to cause gastric bleeding and form ulceration in the gastric lining. NSAIDs are also associated with
3168-465: The heart, suggesting the possibility of relief from pain and inflammation without gastrointestinal irritation, and promising to be a boon for those who had previously experienced adverse effects or had comorbidities that could lead to such complications. Celecoxib is approximately 30 times more potent at inhibiting COX-2 than COX-1, with etoricoxib being 106 times more potent. Between 1996 and 2009, Scott Reuben purportedly conducted clinical research on
3240-405: The high risk of undiagnosed vascular disease . These differential effects are due to the different roles and tissue localisations of each COX isoenzyme. By inhibiting physiological COX activity, NSAIDs may cause deleterious effects on kidney function, and, perhaps as a result of water and sodium retention and decreases in renal blood flow, may lead to heart problems. In addition, NSAIDs can blunt
3312-493: The highest rate of gastric adverse effects, while ibuprofen (lower doses) and diclofenac appear to have lower rates. Certain NSAIDs, such as aspirin, have been marketed in enteric-coated formulations that manufacturers claim reduce the incidence of gastrointestinal ADRs. Similarly, some believe that rectal formulations may reduce gastrointestinal ADRs. However, consistent with the systemic mechanism of such ADRs, and in clinical practice, these formulations have not demonstrated
3384-473: The increased risk of cardiovascular events (heart attack and stroke). By 2005 The New England Journal of Medicine published an editorial accusing the Bombardier et al. of deliberately withholding data. Claire Bombardier, a University of Toronto rheumatologist, had claimed that the VIGOR trial showed that Vioxx 50 mg/day had benefits over naproxen for rheumatoid arthritis, specifically that Vioxx reduced
3456-1013: The intestinal tract. Overexpression of COX-2 produces excess prostaglandins, which have been shown to increase the possibility of colorectal cancer . COX inhibitors have been shown to reduce the occurrence of cancers and precancerous growths. The National Cancer Institute has done some studies on COX-2 and cancer. COX-2 can act as an anti-tumor enzyme, but only in specific cases. The FDA has approved Celebrex for treatment of familial adenomatous polyposis (FAP). COX-2 inhibitors are currently being studied in breast cancer and appear to be beneficial. COX-2 inhibitors have been found to be effective in suppressing inflammatory neurodegenerative pathways, with beneficial results in animal studies for major depressive disorder , as well as schizophrenia , bipolar disorder , and obsessive-compulsive disorder . These need to be confirmed in human clinical trials. Current studies support an association of disorders such as these with chronic inflammation, which appears to decrease with
3528-400: The kidneys' ability to excrete uric acid , and thus may exacerbate these conditions. If a COX-2 inhibitor is taken, a traditional NSAID (prescription or over-the-counter) should not be taken at the same time. Rofecoxib (Vioxx) was shown to produce significantly fewer gastrointestinal adverse drug reactions ( ADRs ) compared with naproxen. The study, the VIGOR trial, raised the issue of
3600-406: The lining of the GI tract (e.g.: a prostaglandin analog misoprostol ). Diarrhea is a common side effect of misoprostol; however, higher doses of misoprostol have been shown to reduce the risk of a person having a complication related to a gastric ulcer while taking NSAIDs. While these techniques may be effective, they are expensive for maintenance therapy. Hydrogen sulfide NSAID hybrids prevent
3672-510: The management of post-operative dental pain following invasive dental procedures such as dental extraction . When not contra-indicated, they are favoured over the use of paracetamol alone due to the anti-inflammatory effect they provide. There is weak evidence suggesting that taking pre-operative analgesia can reduce the length of post operative pain associated with placing orthodontic spacers under local anaesthetic. Based on observational studies and randomized controlled trials , NSAID use
SECTION 50
#17328591312513744-471: The most likely to produce photosensitivity reactions, but other NSAIDs have also been implicated including piroxicam , diclofenac , and benzydamine . Benoxaprofen , since withdrawn due to its liver toxicity , was the most photoactive NSAID observed. The mechanism of photosensitivity, responsible for the high photoactivity of the 2-arylpropionic acids, is the ready decarboxylation of the carboxylic acid moiety . The specific absorbance characteristics of
3816-433: The other compound. Structural analogs are often isoelectronic . Despite a high chemical similarity, structural analogs are not necessarily functional analogs and can have very different physical, chemical, biochemical, or pharmacological properties. In drug discovery , either a large series of structural analogs of an initial lead compound are created and tested as part of a structure–activity relationship study or
3888-479: The overexpressed COX-2, allow p53 to work properly. Functional p53 allows DNA damaged neuroblastoma cells to commit suicide through apoptosis, halting tumor growth. COX-2 up-regulation has also been linked to the phosphorylation and activation of the E3 ubiquitin ligase HDM2 , a protein that mediates p53 ligation and tagged destruction, through ubiquitination . The mechanism for this neuroblastoma HDM2 hyperactivity
3960-523: The patients given rofecoxib (0.4%) compared with those given naproxen (0.1%)" and "patients given naproxen experienced 121 side effects compared with 56 in the patients taking rofecoxib," a "marvellous result for Merck" which "contributed to huge sales of rofecoxib." Merck's scientists incorrectly interpreted the finding as a protective effect of naproxen, telling the FDA that the difference in heart attacks "is primarily due to" this protective effect. In September 2001,
4032-624: The period of the study, COX-2 inhibitors rose from 10.03% of total NSAIDs prescribed by specialty physicians to 29.79%, and from 1.52% to 10.78% of NSAIDs prescribed by primary care physicians (98.23% of NSAIDs and 94.61% of COX-2 inhibitors were prescribed by primary care physicians). For specialty physicians, rofecoxib and celecoxib were third and fifth most frequently prescribed NSAIDs but first and second in cost, respectively; for primary-care physicians they were ninth and twelfth most frequently prescribed NSAIDs and first and fourth in cost. Sales and marketing efforts were supported by two large trials,
4104-479: The production of erythropoietin , resulting in anaemia, since haemoglobin needs this hormone to be produced. The most prominent NSAIDs are aspirin , ibuprofen , and naproxen ; all available over the counter (OTC) in most countries. Paracetamol (acetaminophen) is generally not considered an NSAID because it has only minor anti-inflammatory activity. Paracetamol treats pain mainly by blocking COX-2 and inhibiting endocannabinoid reuptake almost exclusively within
4176-406: The risk of quinolones' adverse central nervous system effects, including seizure. There is an argument over the benefits and risks of NSAIDs for treating chronic musculoskeletal pain. Each drug has a benefit-risk profile and balancing the risk of no treatment with the competing potential risks of various therapies should be considered. For people over the age of 65 years old, the balance between
4248-451: The risk of symptomatic ulcers and clinical upper gastrointestinal events ( perforations , obstructions and bleeding ) by 54%, to 1.4% from 3%, the risk of complicated upper gastrointestinal events (complicated perforations, obstructions and bleeding in the upper gastrointestinal tract ) by 57%, and the risk of bleeding from anywhere in the gastrointestinal tract by 62%. An enormous marketing effort capitalized on these publications; Vioxx
4320-473: The specific drug, its dose and duration of use, but largely include an increased risk of gastrointestinal ulcers and bleeds , heart attack , and kidney disease . The term non-steroidal , common from around 1960, distinguishes these drugs from corticosteroids , another class of anti-inflammatory drugs, which during the 1950s had acquired a bad reputation due to overuse and side-effect problems after their introduction in 1948. NSAIDs work by inhibiting
4392-665: The structure of a particular enzyme involved in their biosynthesis , cyclooxygenase . Prostaglandins whose synthesis involves the cyclooxygenase-I enzyme, or COX-1, are responsible for maintenance and protection of the gastrointestinal tract , while prostaglandins whose synthesis involves the cyclooxygenase-II enzyme, or COX-2, are responsible for inflammation and pain. The existing nonsteroidal anti-inflammatory drugs ( NSAIDs ) differ in their relative specificities for COX-2 and COX-1; while aspirin and ibuprofen inhibit COX-2 and COX-1 enzymes, other NSAIDs appear to have partial COX-2 specificity, particularly meloxicam ( Mobic ). Aspirin
SECTION 60
#17328591312514464-546: The study, men who used NSAIDs regularly were at significantly increased risk of erectile dysfunction. A link between NSAID use and erectile dysfunction still existed after controlling for several conditions. However, the study was observational and not controlled, with low original participation rate, potential participation bias, and other uncontrolled factors. The authors warned against drawing any conclusion regarding cause. The main adverse drug reactions (ADRs) associated with NSAID use relate to direct and indirect irritation of
4536-563: The time of Simmons's work. A settlement was reached in April 2012 in which Pfizer agreed to pay $ 450 million. The other litigation is based on United States Pat. No. 6,048,850 owned by University of Rochester , which claimed a method to treat pain without causing gastro-intestinal distress by selectively inhibiting COX-2. When the patent issued, the university sued Searle (later Pfizer) in a case called, University of Rochester v. G.D. Searle & Co. , 358 F.3d 916 (Fed. Cir. 2004). The court ruled in favor of Searle in 2004, holding in essence that
4608-479: The university had claimed a method requiring, yet provided no written description of, a compound that could inhibit COX-2 and therefore the patent was invalid. In the course of the search for a specific inhibitor of the negative effects of prostaglandins that spared the positive effects, it was discovered that prostaglandins could indeed be separated into two general classes that could loosely be regarded as "good prostaglandins" and "bad prostaglandins", according to
4680-417: The use of COX-2 inhibitors, often in combination with gabapentin or pregabalin , for the prevention and treatment of postoperative pain , research which was found in 2009 to have been faked. Reuben pleaded guilty, paid fines, and served six months in jail, and lost his medical license . A 2009 review of meta-articles used in evidence-based medicine found that while some reviews were no longer valid when
4752-517: The use of COX-2 inhibitors. The inhibition of COX-2 is paramount for the anti-inflammatory and analgesic function of the selective COX-2 inhibitor celecoxib. However, with regard to this drug's promise for the therapy of advanced cancers, it is unclear whether the inhibition of COX-2 plays a dominant role, and this has become a controversial and intensely researched issue. In recent years, several additional intracellular components (besides COX-2) were discovered that appear to be important for mediating
4824-546: The use of NSAID therapy. An estimated 10–20% of NSAID patient's experience dyspepsia , and NSAID-associated upper gastrointestinal adverse events are estimated to result in 103,000 hospitalizations and 16,500 deaths per year in the United States, and represent 43% of drug-related emergency visits. Many of these events are avoidable; a review of physician visits and prescriptions estimated that unnecessary prescriptions for NSAIDs were written in 42% of visits. Aspirin should not be taken by people who have salicylate intolerance or
4896-734: The various individual NSAIDs are small, but there is considerable variation among individual patients in therapeutic response and tolerance to these drugs. About 60% of patients will respond to any NSAID; of the others, those who do not respond to one may well respond to another. Pain relief starts soon after taking the first dose, and a full analgesic effect should normally be obtained within a week, whereas an anti-inflammatory effect may not be achieved (or may not be clinically assessable) for up to three weeks. If appropriate responses are not obtained within these times, another NSAID should be tried. Pain following surgery can be significant, and many people require strong pain medications such as opioids. There
4968-492: Was a significant increase in the rate of vascular events like myocardial infarction or stroke with COX-2 inhibitors compared with placebo . These results led Merck to voluntarily withdraw (rofecoxib) from the market in September 2004 and to regulatory authorities imposing a boxed warning on the label of celecoxib. Traditional NSAIDs were also found to have cardiovascular risks, leading to similar boxed warnings . The cause of
5040-491: Was associated with significantly fewer upper gastrointestinal complications (0.44% vs. 1.27%, p = 0.04), with no significant difference in incidence of cardiovascular events in patients not taking aspirin for cardiovascular prophylaxis . The VIGOR trial results were published in 2000 in the New England Journal of Medicine Bombardier and his research team claimed that there was "an increase in myocardial infarction in
5112-409: Was discovered in 1988 by Daniel Simmons, a Brigham Young University researcher. The mouse COX-2 gene was cloned by UCLA scientist Harvey Herschman, a finding published in 1991. The basic research leading to the discovery of COX-2 inhibitors has been the subject of at least two lawsuits. Brigham Young University has sued Pfizer , alleging breach of contract from relations BYU had with the company at
5184-409: Was the most heavily advertised prescription drug in 2000, and Celebrex the seventh, according to IMS Health . Small tumors of the sympathetic nervous system ( neuroblastoma ) appear to have abnormal levels of COX-2 expressed. These studies report that overexpression of the COX-2 enzyme has an adverse effect on the tumor suppressor, p53 . p53 is an apoptosis transcription factor normally found in
#250749